Background: Virus-associated haemophagocytic syndrome (VAHS) is a fatal complication of viral infections, such as Epstein-Barr virus and H5N1 influenza, that results from macrophage activation and proinflammatory cytokine injuries. The high comorbidity and mortality of current therapy urgently demands an ideal agent based on VAHS pathogenesis. Peroxisome proliferator activated receptor (PPAR) agonists, regulators of metabolic syndrome, can exhibit immunomodulatory effects on macrophage activation and cytokine secretion. Methods: In this study, we adopted rosiglitazone, a PPAR-g agonist, for VAHS control in a Herpesvirus papio (HVP)-infected rabbit model. Various doses of rosiglitazone were orally administered to rabbits on day 7 or day 20 after intravenous challenge with 5×10 7 copies of HVP. Results: The rabbits that received 4 mg/day rosiglitazone had significantly increased survival when treated at an early stage of infection (P<0.01), whereas a higher dose (8 mg/day) was required at the advanced stage of the disease (P<0.05). All rosiglitazone-treated rabbits had significantly improved laboratory parameters and plasma tumour necrosis factor-a levels. Importantly, rosiglitazone could also inhibit viral replication in vitro and in vivo. Conclusions: PPAR agonists could represent a potentially new agent for the therapy of VAHS.
Virus-associated haemophagocytic syndrome (VAHS) is a fatal complication associated with severe viral infections, such as Epstein-Barr virus (EBV) and H5N1 influenza [1] [2] [3] [4] . Previous studies on the pathogenesis of VAHS suggest that this condition results from an aberrant immune response following virus infection [1, 2, 5, 6] . This virus-host interaction could lead to enhanced proinflammatory cytokine secretion and systemic tissue injuries. Clinical signs of VAHS include fever, hepatosplenomegaly, cytopenia and coagulopathy. The disease, if untreated, will progress to the full-blown stage with extensive organ failure, severe cytopenia and florid haemophagocytosis in bone marrow. Hypercytokinemia is a consistent finding and tumour necrosis factor-a (TNF-a) has been identified as one of the candidate cytokines in VAHS pathogenesis [7, 8] . The enhanced TNF-a secretion is reportedly mediated by the NF-κB/SAP/ERK (nuclear factor-κB/SLAM-associated protein/extracellular signal-regulated kinase) signalling pathway that is activated by EBV latent membrane protein 1 in EBV-infected T-cells [1, 9] .
The therapy for VAHS, especially childhood haemophagocytic lymphohistiocytosis (HLH), has significantly improved in the past decade primarily due to the early recognition and treatment of the disease [2, 10] . However, the high comorbidity associated with the current treatment of HLH and H5N1 influenza urgently demand a novel and effective agent to be incorporated into the current protocol based on the VAHS pathogenesis [2] [3] [4] 6] . Peroxisome proliferators activated receptor (PPAR) agonists, in addition to their remarkable effects on the treatment of metabolic syndrome [11, 12] , have been found to exert immunomodulatory effects on T-cell activation, macrophage activation and suppression of proinflammatory cytokine secretion, all of which are characteristic features of VAHS and are primarily
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Efficacy of peroxisome proliferator activated receptor agonist in the treatment of virus-associated haemophagocytic syndrome in a rabbit model Introduction mediated via NF-κB signalling [13] [14] [15] [16] . Preliminary reports have also revealed inhibitory effects of a PPAR-g agonist on replication of HIV and respiratory syncytial virus (RSV) [17, 18] . These combined effects of PPAR agonists suggest their appropriate application in VAHS therapy. A rabbit model of Herpesvirus papio (HVP)-induced VAHS has been established [19, 20] . The HVP virus is an EBV homologue and a HVP-induced VAHS rabbit model manifested clinicopathological features similar to VAHS in humans [21] . We therefore adopted this rabbit model to test the efficacy of rosiglitazone, a PPAR-g agonist, for VAHS therapy at different stages of the disease.
Methods
The rabbit model of HVP-induced VAHS The rabbit VAHS model was previously developed by Hayashi et al. [19] and established in our laboratory using HVP [22] . The HVP viruses were harvested from culture supernatants of 594S cells, the virus titres adjusted to 10 8 copies/ml and stored at -70°C until use. A total of 5×10 7 copies of HVP were inoculated into rabbits by intravenous injection. On the basis of the virus-host interaction, as previously established [22] , rabbits were started to be fed orally with rosiglitazone (Avandia, GSK, Philadelphia, PA, USA) on day 7 (group A) or day 20 (group B) after HVP inoculation, representing the early and late stage of the disease, respectively. The treatment was continued until the end of this study. Serial examinations of clinical and laboratory parameters were recorded. This animal study has been performed under the approval of the Committee of Animal Centre of National Cheng Kung University Medical School, Tainan, Taiwan.
Histopathological examinations
The rabbits were autopsied after death or sacrificed under euthanasia on day 45 after infection with an overdose of pentobarbital sodium (MTC Pharmaceuticals, Cambridge, Canada). Multiple organs including the spleen, lymph nodes, liver, kidneys, lungs and spinal cord were harvested, examined macroscopically and then fixed with 10% neutral formalin. The formalin-fixed, paraffin-embedded tissue blocks were sectioned at 3 mM thickness and studied for conventional histopathology.
Detection of HVP in tissues and quantification of viral loads by real-time PCR
The HVP viruses in tissues were detected by in situ hybridization of EBV-encoded RNA-1 (EBER-1), as previously described [22] . Viral DNA in plasma or culture supernatant was extracted with the QIAamp DNA Mini kit (QIAGEN GmbH, Hilden, Germany) according to the manufacturer's protocol. For HVP virus determination, the primers used in this assay were HPNA2-1485S and HPNA2-1691A, as described previously [22] . The HVP Taqman probe was 5′-FAM-AACACCAAGTCCGC CAATACTC-3′TAMRA.
Detection of TNF-a in rabbit plasma
For the determination of rabbit plasma TNF-a, purified antirabbit TNF-a antibody (BD Bioscience, San Diego, CA, USA) was used as a capture antibody for ELISA. After blocking, recombinant rabbit TNF-a (BD Bioscience) or rabbit plasma were added and incubated for 2 h. The plate was washed and biotin-conjugated antirabbit TNF-a antibody (BD Bioscience) mixed with strepavidin-horseradish peroxidase (BD Bioscience) was added. After incubation for 1 h, the plate was washed again and tetramethylbenzidine substrate was applied to the plate for 20 min. Finally, the plate was measured at OD 490 nm using an ELISA reader after adding stop solution.
Detection of antibody-coated red blood cells by flow cytometry
Our previous studies have demonstrated that antibodycoated red blood cells (RBCs) play a crucial role in RBC phagocytosis and can predict the subsequent development of VAHS [22] . The titre of antibody-coated RBCs is thus a good indicator of VAHS severity. For the detection of antibody-coated RBCs, blood samples were collected pre-and post-HVP inoculation and then incubated with fluorescein isothiocyanate (FITC)-labelled antirabbit immunoglobulin (DAKO, Glostrup, Denmark) for 30 min. After setting forward scatter and side scatter detectors to log mode and gating RBC region, the surface fluorescence on the rabbit RBC was measured by fluorescence-activated cell sorting (FACS, Calibur; Becton Dickinson, Franklin Lakes, NJ, USA).
Demonstration of in vitro inhibition of viral replication by rosiglitazone
To test whether rosiglitazone can inhibit viral replication, the EBV replicative system and its lytic antigens were adopted for this study. This approach was employed because antibodies against the HVP lytic antigens were not available and because EBV and HVP are close homologues [21] .
Immunofluorescence assay to detect viral antigens
For the detection of EBV viral antigens, the marmoset cell line B95.8 (which contains EBV) was used in this study. B95.8 cells were treated with different dosages of rosiglitazone for 24 h. Cells were harvested and then seeded on 12-well slides. Slides were air-dried and fixed with acetone for 5 min at 4°C. Anti-EBV early antigen D (EAD) and viral capsid antigen (VCA) antibodies were applied to the slides for 30 min and then washed with phosphate-buffered saline (PBS). The secondary antibody, Alexa Fluor ® 488 goat antimouse immunoglobulin G (H+L; Invitrogen, Carlsbad, CA, USA) was then added to the slides for another 30 min. After washing, slides were mounted with glycerol containing 4′,6-diamidino-2-phenylindole (DAPI) for nuclear staining control and then observed under fluorescent microscopy.
Western blot analysis of the inhibition of viral replication by rosiglitazone in the B95.8 cell line
To clarify whether rosiglitazone can inhibit viral replication, the EBV-containing marmoset cell line B95.8 was used. Phorbol ester (TPA) was used to induce the lytic cycle of EBV. The EBV lytic proteins VCA and EAD were detected by immunofluorescence. Western blot analysis was also performed on the induction of EBV lytic protein EAD. Rosiglitazone at different dosages was examined for the inhibitory effect on lytic induction.
Statistical analysis
Survival of the rabbits in each group, as compared with the infected, untreated control rabbits, was analysed by the log rank test. TNF-a and viral loads from plasma among different groups were analysed by the KruskalWallis test following the Dunn's post test if P<0.05. All of the tests used the GraphPad Prism 4.0 software. Statistical significance was defined at P<0.05.
Results

Gross observations and histopathological examinations
Treatment with rosiglitazone was started on either day 7 (early stage of HVP infection, group A) after HVP inoculation, when plasma TNF-a and abnormal laboratory parameters started to be detected, or on day 20 after inoculation (advanced stage of the disease, group B) when autoantibody-coated RBCs appeared and haemophagocytosis was observed in tissues, representing advanced or full-blown disease activities ( Figure 1A ). The laboratory parameters such as platelet count usually showed a remarkable decrease of beyond 50% at this advanced stage.
A total of 38 rabbits were used in this study. Among these 38 rabbits, 36 were infected with HVP and the 2 uninfected rabbits were used as normal control and drug toxicity control (rosiglitazone, 8 mg/day). Eight rabbits were infected but received no rosiglitazone treatment (infected and untreated control). Rosiglitazone was administered to 28 of the HVP-infected rabbits and these were divided into group A (16 rabbits) and group B (12 rabbits). The rosiglitazone dosages were further stratified into three subgroups among group A rabbits: 1 mg/day (6 rabbits), 2 mg/day (5 rabbits) and 4 mg/day (5 rabbits). Higher rosiglitazone dosages were administered to group B rabbits and these were divided into two subgroups: 4 mg/day (6 rabbits) and 8 mg/day (6 rabbits).
The HVP-uninfected rabbits for the drug toxicity control remained healthy throughout the course of the experiment. Therefore, a high dose of 8 mg/day rosiglitazone showed no detectable toxicity in rabbits. However, the 8 HVP-infected but untreated rabbits developed clinical illness, such as loss of appetite, on day 22-30 and all died before day 35. Necropsies of the rabbits in the untreated group revealed swollen lymph nodes, hepatosplenomegaly and pulmonary congestion. The rabbits fed with lower doses (1 and 2 mg/day rosiglitazone) in group A and the 4 mg/day subgroup in group B had necropsy findings similar to those of the untreated group, albeit to a milder degree. By contrast, the rabbits receiving 8 mg/day of rosiglitazone in group B had mild to moderate abnormal findings, such as the size of the spleen and liver at day 45 post-inoculation ( Figure 1B ). The 4 mg/day subgroup rabbits in group A had relatively normal gross findings.
Histopathological examinations from infected but untreated rabbits revealed progressive lymphoid depletion in spleen and lymph nodes and extensive necrosis of bone marrow ( Figure 1C ). Haemophagocytosis was frequently observed in lymph nodes and spleen. Many infiltrating lymphocytes were observed in portal areas of livers ( Figure 1C ) and in perivascular areas in kidneys and lungs (pictures not shown). Similar findings were also observed in the low-dose subgroups of rabbits (1 and 2 mg/day in group A and 4 mg/day in group B). However, in the 4 mg/day rosiglitazone-treated rabbits in group A, the spleen and lymphoid organs showed relatively normal findings, with even myeloid hyperplasia in bone marrow. In the 8 mg/day treated rabbits in group B, mild to moderate lymphoid hypoplasia, congestion and occasional RBC phagocytosis were observed in the spleen and lymph nodes. The lymphoid infiltration in the portal areas of the liver was relatively mild ( Figure 1C ). The uninfected rabbit receiving 8 mg/ day rosiglitazone showed normal microscopic findings similar to those of the normal control rabbit (data not shown), indicating no evidence of drug toxicity at this high dose.
Rosiglitazone therapy improves the survival rate of HVP-infected rabbits
All the rabbits in the untreated group died between day 25 and day 35 with a median survival of 28 days. In the treated group A, the rabbits that received 1 and 2 mg/day rosiglitazone had improved survival as compared with the untreated group, with a median survival of 36 days (1 mg/day; P=0.0125) and 37 days (2 mg/day; P=0.0024). The rabbits that received 4 mg/ day rosiglitazone in group A showed a significantly [22] , the rabbits were fed orally with rosiglitazone on day 7 (group A) or day 20 (group B) after HVP inoculation. (B) Gross features of the spleen in HVP-infected rabbits. The HVP-infected, untreated rabbits had enlarged spleens. In the treated rabbits, the spleen size was decreased significantly. (C) Representative histopathological features of bone marrow, spleen and liver in normal control (control), HVP-infected but without treatment (HVP), 4 mg/day rosiglitazone-treated rabbits in group A and 8 mg/day rosiglitazone-treated rabbits in group B. All sections were stained with haemotoxylin and eosin (magnification ×200). The untreated HVP-infected rabbits had marrow necrosis, depletion of the lymphoid system with red blood cell (RBC) phagocytosis (inset, ×1,000 magnification), and portal infiltration of lymphoid cells with mild fatty liver. The rabbits treated with 4 mg/day rosiglitazone in group A had much improved results, whereas the rabbits treated with 8 mg/day rosiglitazone in group B still showed mild to moderate pathology, although were much improved as compared with the untreated rabbits. TNF-a, tumour necrosis factor-a; VAHS, virus-associated haemophagocytic syndrome.
prolonged survival: at the end of the study (day 45), 3 of 5 rabbits still survived and looked healthy, as described above in the histopathological examination (P=0.0036; Figure 2 , group A). But, if treated at a late or full-blown disease stage (group B), only rabbits treated with the higher dose of 8 mg/day rosiglitazone showed significantly improved survival (P=0.0475; Figure 2 , group B).
Laboratory parameters and plasma TNF-a levels
The rabbits in both therapeutic groups showed improved laboratory parameters in a dose-dependent manner ( Figure 3 ). Antibody-coated RBC titres, an indicator of RBC phagocytosis [22] , had a dosedependent, delayed emergence in plasma ( Figure 3A) . The platelet counts were also more stable and had a dose-dependent effect in both groups ( Figure 3B ). However, the platelet counts in group B rabbits continued to decrease to severe thrombocytopenic levels at day 45. The results of TNF-a production in each group of rabbits are shown in Figure 3C . Plasma TNF-a was detectable on day 12 after HVP inoculation in the untreated group. There was a wide spectrum of TNF-a levels: one rabbit had an unusually high level up to 50 ng/ml. In untreated rabbits, enhanced TNF-a levels persisted, but still fluctuated, prior to death (Figure 3C, day 26 ). TNF-a production showed a delayed increase and levels were maintained at relatively low levels (<1 ng/ml) in most of the rosiglitazone-treated group A rabbits, except the 1 mg/day subgroup which had high levels of TNF-a ( Figure 3C, upper panel) . On day 26, the TNF-a levels in the 4 mg/day group A rabbits remained at undetectable levels (P<0.05, as compared with untreated group). In group B rabbits, the TNF-a levels returned from the mildly increased level before therapy to undetectable levels 3 days after therapy (day 23) in both the 4 mg/day and 8 mg/day subgroups (P<0.01), indicating a therapeutic effect of rosiglitazone. However, TNF-a levels increased again on day 26 along with the disease progression.
Detection of HVP in tissues and quantification of viral loads in plasma
In situ EBER-1 hybridization was performed on formalin-fixed tissues. The EBER-1 signals in the infiltrating lymphocytes of spleen, lymph node and liver were much lower in the treated groups than in the untreated rabbits ( Figure 4A ). There was a dosagedependent effect in both groups, especially in the 4 mg/day-treated rabbits in group A, which showed a remarkable decrease of the EBER-1 signals. In parallel to the results at the tissue level, plasma viral loads from rosiglitazone-treated groups showed a significant decrease of around half a log scale as compared with that in the untreated groups on day 23 and day 26 (P<0.05); again, this decrease occurred in a dosagedependent manner ( Figure 4B ). Rosiglitazone-treated rabbits showed better survival times than untreated rabbits in a dosage-dependent manner in both groups. A higher dosage of 8 mg/day was required to achieve improved survival if treated at the advanced stage of disease. Rosiglitazone inhibits lytic production of EBV in B95.8 cells (C) Western blotting also showed that EBV-EAD expression was downregulated by rosiglitazone in a dose-dependent manner. TPA: 50 ng/ml; R1, R10, R50 and R100: 1 mM, 10 mM, 50 mM and 100 mM rosiglitazone, respectively. Actin was used as internal control in western blot analysis.
EBV-VCA ( Figure 5A ) and EBV-EAD ( Figure 5B ) could be induced by TPA and were then downregulated in a dose-dependent manner by rosiglitazone treatment, as assayed by immunofluorescence microscopy. Using western blot analysis, the same findings were observed for the expression of EAD ( Figure 5C ). Taken together, these data suggest that rosiglitazone can inhibit the lytic activation of EBV and this is probably also true for HVP, explaining the decrease of HVP viral loads in the rosiglitazone-treated rabbits.
Discussion
In this study we demonstrated for the first time that the PPAR-g agonist rosiglitazone could significantly improve the therapy of VAHS in a HVP-infected rabbit model. Rosiglitazone was found to suppress the secretion of the proinflammatory cytokine TNF-a and also to improve laboratory parameters and survival. Interestingly, rosiglitazone could inhibit, although not eliminate, viral replication in vitro and in vivo. Rosiglitazone or other PPAR agonists might therefore represent potential agents for consideration as alternative or combination drugs for VAHS therapy. PPAR agonists are part of current therapies for metabolic syndrome and related disorders, such as nonalcoholic fatty liver [23] [24] [25] [26] , and might also exhibit a wide spectrum of biological effects, including regulation of the immune system and anti-inflammatory properties [13, 27, 28] . PPAR agonists might also function as anticancer agents [29] [30] [31] . The main mechanistic action of PPAR agonists on metabolic syndrome, on inflammation and on tumours is mediated mainly through the inhibition of NF-κB signalling, which is one of the key pathways involved in inflammation and cancer development [32] [33] [34] . The pathogenesis of VAHS is reportedly mediated via the NF-κB signal pathway to activate TNF-a and proinflammatory cytokines [1, 9] . In this study, we confirmed that the plasma TNF-a levels showed a significant reduction after the institution of rosiglitazone on day 12 of group A rabbits. The rosiglitazone-treated rabbits revealed remarkable effects on ameliorating tissue injuries of the lymphoid system, liver and bone marrow. Degrees of macrophage activation and RBC phagocytosis were also significantly decreased and correlated with the delayed emergence and decreased titres of serum anti-RBC antibodies. Similar to PPAR agonists, the lipid-lowering statins are also known to modulate and ameliorate bacterial sepsis. This effect has also been reported in the literature to be mediated via the inhibition of proinflammatory cytokine secretion and of NF-κB signalling [35] [36] [37] .
One important, yet unexpected, observation of this study was the remarkable decrease of serum viral loads in the rosiglitazone-treated groups of HVP-infected rabbits. Similar observations were noted in EBER-1 in situ hybridization on the spleen, lymph node and liver, as compared with the untreated group on day 45. Although the HVP virus in our study persisted at the end of the study period on day 45, a characteristic for herpes virus infection, the inhibition of viral replication by rosiglitazone was further supported by in vitro studies using the HVP homologue EBV. Previous studies revealed that PPAR agonists could also inhibit the replication of HIV and RSV [17, 18] . The exact mechanism for the inhibition of viral replication by PPAR agonists remains to be investigated in the future [38] [39] [40] .
On the basis of the laboratory and survival data obtained in this study, we showed that rosiglitazone has a significant effect on the suppression of TNF-a levels and viral loads, and could improve the survival time for rabbits if treated at an early stage of infection. However, a higher dosage of the drug is required to ameliorate VAHS if treated at the advanced stage of the disease and only suboptimal therapeutic effects could be achieved. Rabbits in the advanced stage of VAHS usually exhibited severe bone marrow depletion, severe lymphoid depletion, extensive tissue injuries and superimposed infections, all of which make the prognosis ominous. Lastly, and importantly, the introduction of PPAR agonists in VAHS therapy will shed light on the therapy of H5N1 influenza, as the high morbidity and mortality of H5N1 influenza has been reported to result from lethal proinflammatory cytokine injuries in systemic organs and tissues in response to H5N1 virus [41] . As mentioned above, the combined effects of PPAR agonists on the regulation of macrophage activation, the suppression of proinflammatory cytokine secretion and the inhibition of viral replication make PPAR agonists a new agent for improving the control of severe viral infection and probably other cytokine immune disorders.
